Results 11 to 20 of about 15,396 (182)

Effectiveness of pneumococcal conjugate vaccines against invasive pneumococcal disease among children under five years of age in Africa: A systematic review.

PLoS ONE, 2019
BackgroundDespite the widespread implementation of the pneumococcal conjugate vaccine, Streptococcus pneumoniae remains the leading cause of severe pneumonia associated with mortality among children less than 5 years of age worldwide, with the highest ...
James Samwel Ngocho, Best Magoma, Gaudencia Alois Olomi, Michael Johnson Mahande, Sia Emmanueli Msuya, Marien Isaäk de Jonge, Blandina Theophil Mmbaga   +6 more
doaj   +1 more source

Invasive Pneumococcal Disease 3 Years after Introduction of 10-Valent Pneumococcal Conjugate Vaccine, the Netherlands

Emerging Infectious Diseases, 2015
Three years after a 7-valent pneumococcal conjugate vaccine was replaced by a 10-valent pneumococcal conjugate vaccine in the Netherlands, we observed a decrease in incidence of invasive pneumococcal disease caused by Streptococcus pneumoniae serotypes 1,
Mirjam J. Knol, Gertjan H.J. Wagenvoort, Elisabeth A.M. Sanders, Karin Elberse, Bart J. Vlaminckx, Hester E. de Melker, Arie van der Ende   +6 more
doaj   +1 more source

Invasive pneumococcal infection due to serotype 15A after the pneumococcal conjugate vaccine implementation in Turkey

Human Vaccines & Immunotherapeutics, 2017
Invasive pneumococcal infections among children are a serious public health problem in many countries, including Turkey. Pneumococcal conjugate vaccine has been included in Turkey's National Immunization Programme since 2009.
Ayşe Büyükcam, Hüseyin Güdücüoğlu, Kamuran Karaman, Venhar Gürbüz, Emil Aliyev, Ateş Kara, Mehmet Ceyhan   +6 more
doaj   +1 more source

Epidemiology of non-vaccine serotypes of Streptococcus pneumoniae before and after universal administration of pneumococcal conjugate vaccines

Human Vaccines & Immunotherapeutics, 2021
The universal administration of pneumococcal conjugate vaccines (PCVs) had been demonstrated as an effective way to prevent Streptococcus pneumoniae infection.
Qian-qian Du, Wei Shi, Dan Yu, Kai-hu Yao   +3 more
doaj   +1 more source

Adesão às novas vacinas conjugadas. Vacina anti-meningocócica e anti-pneumocócica.

Acta Médica Portuguesa, 2004
The new conjugate vaccines against group C meningococcal infection and pneumococcal infection were introduced in Portugal in 2001. In 2001/2002, the media published several alarming news on meningococcal disease and there was an increased demand of those
Laurinda De Queirós, Luis Castro, Maria Carmo Ferreira, Guilherme Gonçalves   +3 more
doaj   +1 more source

Uptake of Pneumococcal Vaccines Among U.S. Adults After 2022 Update to Recommendations

AJPM Focus
Introduction: Updated recommendations for adult pneumococcal vaccination in the U.S. (publication date: January 27, 2022) incorporated 2 new vaccines (15- and 20-valent pneumococcal conjugate vaccines), removed 13-valent pneumococcal conjugate vaccine ...
Ahuva Averin, MPP, Jeffrey Vietri, PhD, Adriano Arguedas Mohs, MD, Sarah J. Willis, PhD, MPH, Alexander Lonshteyn, PhD, Derek Weycker, PhD   +5 more
doaj   +1 more source

Genetic diversity of Streptococcus pneumoniae causing meningitis and sepsis in Singapore during the first year of PCV7 implementation

Emerging Microbes and Infections, 2014
Streptococcus pneumoniae is a major cause of sepsis, meningitis and respiratory disease worldwide. Pneumococcal conjugate vaccines (PCVs) have now been implemented in many countries worldwide, including Singapore.
Elita Jauneikaite, Johanna Mary Carnon Jefferies, Nicholas William Vere Churton, Raymond Tzer Pin Lin, Martin Lloyd Hibberd, Stuart Charles Clarke   +5 more
doaj   +1 more source

A brief history of and future prospects for pneumococcal vaccination in Malaysia

Pneumonia, 2023
Pneumococcal pneumonia remains a significant global public health issue. Malaysia has recently added the 10 valent pneumococcal conjugate vaccine to its national immunisation programme.
Alex J. J. Lister, Evelin Dombay, David W. Cleary, Lokman H. Sulaiman, Stuart C. Clarke   +4 more
doaj   +1 more source

EXPERIENCE OF APPLICATION AND SAFETY ASSESSMENT OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN UNDER-5 CHILDREN

Педиатрическая фармакология, 2014
Compulsory use of the 7-valent pneumococcal conjugate vaccine in the framework of national pediatric immunization schedules of the developed countries resulted in significant decrease in the prevalence of the pneumococcal infections induced by the ...
M. V. Fedoseenko, D. A. Novikova, N. E. Tkachenko, M. I. Broeva, T. A. Grechukha, A. G. Gaivoronskaya, V. V. Chernikov   +6 more
doaj   +1 more source

Clinical and bacteriological characteristics of invasive pneumococcal disease after pneumococcal 10-valent conjugate vaccine implementation in Salvador, Brazil

Brazilian Journal of Infectious Diseases, 2016
Invasive pneumococcal disease is a relevant public health problem in Brazil, especially among children and the elderly. In July/2010 a 10-valent pneumococcal conjugate vaccine was introduced to the immunization schedule of Brazilian children under two ...
Carolina Regis Leite, Jailton Azevedo, Vivian Santos Galvão, Otávio Moreno-Carvalho, Joice Neves Reis, Cristiana Nascimento-Carvalho   +5 more
doaj   +1 more source